A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation
- PMID: 31220351
- PMCID: PMC6819202
- DOI: 10.1002/hep.30828
A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation
Abstract
Loss of muscle mass and function, or sarcopenia, is a common feature of cirrhosis and contributes significantly to morbidity and mortality in this population. Sarcopenia is a main indicator of adverse outcomes in this population, including poor quality of life, hepatic decompensation, mortality in patients with cirrhosis evaluated for liver transplantation (LT), longer hospital and intensive care unit stay, higher incidence of infection following LT, and higher overall health care cost. Although it is clear that muscle mass is an important predictor of LT outcomes, many questions remain, including the best modality for assessing muscle mass, the optimal cut-off values for sarcopenia, the ideal timing and frequency of muscle mass assessment, and how to best incorporate the concept of sarcopenia into clinical decision making. For these reasons, we assembled a group of experts to form the North American Working Group on Sarcopenia in Liver Transplantation to use evidence from the medical literature to address these outstanding questions regarding sarcopenia in LT. We believe sarcopenia assessment should be considered in all patients with cirrhosis evaluated for liver transplantation. Skeletal muscle index (SMI) assessed by computed tomography constitutes the best-studied technique for assessing sarcopenia in patients with cirrhosis. Cut-off values for sarcopenia, defined as SMI < 50 cm2 /m2 in male and < 39 cm2 /m2 in female patients, constitute the validated definition for sarcopenia in patients with cirrhosis. Conclusion: The management of sarcopenia requires a multipronged approach including nutrition, exercise, and additional pharmacological therapy as deemed necessary. Future studies should evaluate whether recovery of sarcopenia with nutritional management in combination with an exercise program is sustainable as well as how improvement in muscle mass might be associated with improvement in clinical outcomes.
© 2019 by the American Association for the Study of Liver Diseases.
Conflict of interest statement
Conflict of interest:
None.
Figures
References
-
- Montano-Loza AJ, Meza-Junco J, Baracos VE, Prado CM, Ma M, Meeberg G, et al. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. Liver Transpl 2014;20:640–648. - PubMed
-
- van Vugt JL, Levolger S, de Bruin RW, van Rosmalen J, Metselaar HJ, JN IJ. Systematic Review and Meta-Analysis of the Impact of Computed Tomography-Assessed Skeletal Muscle Mass on Outcome in Patients Awaiting or Undergoing Liver Transplantation. Am J Transplant 2016;16:2277–2292. - PubMed
-
- Yadav A, Chang YH, Carpenter S, Silva AC, Rakela J, Aqel BA, et al. Relationship between sarcopenia, six-minute walk distance and health-related quality of life in liver transplant candidates. Clin Transplant 2015;29:134–141. - PubMed
Publication types
MeSH terms
Grants and funding
- K23 AG048337/AG/NIA NIH HHS/United States
- R21 AA022742/AA/NIAAA NIH HHS/United States
- U01 AA021890/AA/NIAAA NIH HHS/United States
- U01 AA026976/AA/NIAAA NIH HHS/United States
- P50 AA024333/AA/NIAAA NIH HHS/United States
- U01 AA026975/AA/NIAAA NIH HHS/United States
- U01 DK061732/DK/NIDDK NIH HHS/United States
- UL1 TR002548/TR/NCATS NIH HHS/United States
- R01 GM119174/GM/NIGMS NIH HHS/United States
- R21 AR071046/AR/NIAMS NIH HHS/United States
- R01 DK113196/DK/NIDDK NIH HHS/United States
- R01 AG059183/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical